

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of reducing, or inhibiting invasiveness and metastasis of tumor cells in a subject, wherein the tumor cells produce Gb₃, comprising administering to the subject a therapeutically effective amount of a B-subunit of Shiga toxin, wherein the B-subunit of Shiga toxin is Stx1B or Stx2B.
2. (Original) The method of claim 1, wherein the tumor cells are colon tumor cells.
3. (Previously Presented) The method of claim 1, wherein the tumor cells are from a tissue selected from the group consisting of: colon, lung, brain, skin, ovary, pancreas, liver, stomach, bladder, bone, testicle, uterus, adipose tissue, throat, kidney, tongue, pituitary gland, thyroid, lymphoid tissue, eye, and cervix.
4. (Cancelled)
5. (Cancelled)
6. (Previously Presented) The method of claim 1, wherein the therapeutically effective amount of the B-subunit of Shiga toxin is administered prior to the onset of metastasis by the tumor cells.
7. (Previously Presented) The method of claim 1, wherein the therapeutically effective amount of the B-subunit of Shiga toxin is administered subsequent to the onset of metastasis by the tumor cells.
8. (Previously Presented) The method of claim 1, further comprising administering to the subject a therapeutically effective amount of radiation.

9. (Previously Presented) The method of claim 1, further comprising administering to the subject a therapeutically effective amount of at least one chemotherapeutic agent.

10. (Cancelled)

11. (Previously Presented) The method of claim 1, wherein the subject is a human.

12. (Previously Presented) The method of claim 1, wherein the B subunit of Shiga toxin is conjugated to a therapeutic moiety.

13. - 17. (Cancelled)

18. (Previously Presented) A method of reducing, or inhibiting invasiveness and metastasis of colon tumor cells in a subject, wherein the tumor cells produce Gb₃, comprising administering to the subject a therapeutically effective amount of a B-subunit of Shiga toxin.